Government of Saskatchewan ministries, Crown corporations and organizations are implementing contingency plans to minimize the impacts of postal service disruption.

Les ministères, sociétés d’État et organismes du gouvernement de la Saskatchewan mettent en œuvre des plans d’urgence (en anglais) visant à réduire les répercussions de l’interruption du service des postes.

Google Translate Disclaimer

A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow box in the right or left rail that resembles the link below. The home page for French-language content on this site can be found at:

Renseignements en Français

Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.

Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).

Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.

Expanded Multiple Sclerosis Drug Coverage For Patients

Released on May 1, 2019

Effective May 1, Saskatchewan residents now have access to another treatment for multiple sclerosis (MS), Ocrevus.
Ocrevus is the first MS medication approved to treat early primary progressive MS, and the thirteenth option for patients with relapsing remitting MS, the most common form of the condition.

“Our government is committed to providing Saskatchewan residents with better access to innovative new treatment options,” Health Minister Jim Reiter said.  “Ocrevus will be the first drug treatment option approved for the primary progressive form of multiple sclerosis.  It offers a treatment option that may slow the progression of multiple sclerosis and improve patients’ quality of life.”

The Saskatchewan Formulary offers a variety of options for MS treatment.  Ocrevus is the first that can be used to treat both primary progressive MS and relapsing remitting MS.  Last year, the provincial government spent about $17 million on MS medications for eligible patients.

Multiple Sclerosis is an autoimmune disease that attacks the central nervous system and leads to a progressive loss of motor skills.  An estimated 3,700 people in Saskatchewan live with MS.

For more information on the approval process and income-assisted programs, contact the Drug Plan and Extended Benefits Branch at 1-800-667-7581 or 306-787-3317 in Regina.

-30-

For more information, contact:

Colleen Book
Health
Regina
Phone: 306-787-4083
Email: media@health.gov.sk.ca

We need your feedback to improve saskatchewan.ca. Help us improve